alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Form of Options granted to Executive Officers



 








Exhibit 10.42

 




	
Entrada Networks
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	
OPTIONS GRANTED TO EXECUTIVE OFFICERS
	 	 	 	 	 
	
AS OF 10/31/2004
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	
Option
	
Expiration
	
Remaining
	
Option
	
Shares
	
Shares

	
Name
	
Number
	
Date
	
Date
	
Life in Years
	
Price
	
Outstanding
	
Exercisable

	 	 	 	 	 	 	 	 
	
Chadha, Kanwar
	
A
	
4/30/2004
	
4/30/2014
	
9.50 
	
$0.1700
	
200,000 
	
0

	President and CEO 	
B
	
2/3/2003
	
2/3/2013
	
8.26 
	
$0.2200
	
125,111 
	
125,111

	
 
	
C
	
2/3/2003
	
2/3/2013
	
8.26 
	
$0.2200
	
34,889 
	
34,889

	
 
	
D
	
2/3/2003
	
2/3/2013
	
8.26 
	
$0.2200
	
22,857 
	
22,857

	
 
	
E
	
2/3/2003
	
2/3/2013
	
8.26 
	
$0.2200
	
57,143 
	
57,143

	
 
	
F
	
2/3/2003
	
2/3/2013
	
8.26 
	
$0.2200
	
6,190 
	
6,190

	
 
	
G
	
2/3/2003
	
2/3/2013
	
8.26 
	
$0.2200
	
393,810 
	
393,810

	
 
	
H
	
2/3/2003
	
2/3/2013
	
8.26 
	
$0.2200
	
20,000 
	
20,000

	
 
	
I
	
4/30/2003
	
4/30/2013
	
8.50 
	
$0.2800
	
150,000 
	
56,250

	 	 	 	 	 	 	 	 
	 	 	 	 	
TOTALS
	 	
1,010,000 
	
716,250

	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	
Sethi, Davinder
	
A
	
9/28/2001
	
9/28/2011
	
6.91 
	
$0.1100
	
50,000 
	
50,000

	
Chief Financial Officer
	
B
	
10/31/2001
	
10/31/2011
	
7.00 
	
$0.1500
	
50,000 
	
50,000

	
 
	
C
	
10/31/2001
	
10/31/2011
	
7.00 
	
$0.1500
	
400,000 
	
300,000

	
 
	
D
	
2/3/2003
	
2/3/2013
	
8.26 
	
$0.2200
	
100,000 
	
100,000

	
 
	
E
	
3/29/2004
	
3/29/2014
	
9.41 
	
$0.2600
	
50,000 
	
0

	
 
	
F
	
4/30/2003
	
4/30/2013
	
8.50 
	
$0.2800
	
100,000 
	
37,500

	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	
750,000 
	
537,500




 

 

 

 



	 
	 	 	 
	





	 


FORM OF OPTIONS GRANTED TO EXECUTIVE OFFICERS




Notice of Grant of Stock Options

and Option Agreement

Entrada Networks

ID: 33-0676350

5755 Oberlin Drive, Suite 204

San Diego, CA 92121







Option Number:   00000000

Plan:     2000







ID:




Effective                  , you have been granted a(n) Incentive Stock Option to buy                          shares of Entrada Networks (the Company) stock at $                            per share.The total option price of the shares granted is $                                    

 

Shares in each period will become fully vested on the date shown.

 

        Shares    Vest Type    Full Vest    Expiration

 

On Vest Date                                                                                                             

Monthly                                                                                                                     







By your signature and the Company's signature below, you and the Company agree that these options

are granted under and governed by the terms and conditions of the Company's Stock Option Plan as

amended and the Option Agreement, all of which are attached and made a part of this document.

 

 

Entrada Networks




                                                                                     

 

Date

 

                                                                                              

 

Date
No. 09-10213.

#### In re Charles D. Minor, Petitioner.

562 U.S. 822, 131 S. Ct. 381,

178 L. Ed. 2d 17,

2010 U.S. LEXIS 6676.

October 4, 2010.

Motion of petitioner for reconsideration of order denying leave to proceed in forma pauperis denied.

Justice Kagan took no part in the consideration or decision of this motion.
Exhibit 32.1CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002I, Leonard R. Stein-Sapir, Chairman of the Board and Chief Executive Officer of Morgan’sFoods, Inc. (the “Company”), hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of2002, that: (1) The Quarterly Report on Form 10-Q of the Company for the period ended November4, 2007, (the “Report”), which this certification accompanies, fully complies with therequirements of Section 13(a) of the Securities Exchange Act of 1934; and  (2) The information contained in the Report fairly presents, in all materialrespects, the financial condition and results of operations of the Company.Dated: December 19, 2007           /s/ Leonard R. Stein-Sapir   Leonard R. Stein-Sapir, Chairman of the Board and   Chief Executive Officer  
18
##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM 10-K/A
 Amendment No. 1
 (Mark One)
 þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE
SECURITIES EXCHANGE ACT OF 1934
 For the fiscal year ended December 31, 2006
 OR
 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE
SECURITIES EXCHANGE ACT OF 1934
 For the transition period from  to
 Commission file number: 0-21863
 EPIX PHARMACEUTICALS, INC.
 (Exact name of registrant as specified in its charter)
 Delaware(State or other jurisdiction 
of incorporation or organization)
    
    04-3030815(I.R.S. Employer Identification No.)4 Maguire Road, Lexington, Massachusetts(Address of principal executive offices)
    
    02421(Zip Code)
 Registrants telephone number, including area code:
(781) 761-7600
Securities registered pursuant to Section 12(b) of the Exchange Act:
 Title of Each Class
    
    Name of Each Exchange on Which RegisteredCommon Stock, $0.01 par value per share
    
    The NASDAQ Stock Market LLC
 Securities registered pursuant to Section 12(g) of the Exchange Act:
 NONE
 o þ
 o þ
 þ o
 þ
  o þ o
 o þ
   DOCUMENTS INCORPORATED BY REFERENCE




---



TABLE OF CONTENTS  EXPLANATORY NOTESIGNATURESEXHIBIT INDEXEX-32 Section 906 CEO & CFO Certification    Table of Contents  
 EXPLANATORY NOTE




---



##### Table of Contents



SIGNATURES
  EPIX PHARMACEUTICALS, INC.By:
    /s/  KIM C. DRAPKINKim C. Drapkin, CPAChief Financial Officer
(Principal Financial and Accounting Officer)  POWER OF ATTORNEY AND SIGNATURES
   Signature
    
    Title
    
    Date/s/ MICHAEL G. KAUFFMAN

Michael G. Kauffman, M.D., Ph.D.
    
    Chief Executive Officer and Director
(Principal Executive Officer)
    
    April 11, 2007/s/ KIM C. DRAPKIN

Kim C. Drapkin, CPA
    
    Chief Financial Officer
(Principal Financial and Accounting
Officer)
    
    April 11, 2007/s/ CHRISTOPHER F.O. GABRIELI

Christopher F.O. Gabrieli
    
    Chairman of the Board of Directors
    
    April 11, 2007/s/ FREDERICK FRANK

Frederick Frank
    
    Vice Chairman of the Board of Directors
    
    April 11, 2007/s/ MICHAEL GILMAN

Michael Gilman, Ph.D.
    
    Director
    
    April 11, 2007/s/ MARK LEUCHTENBERGER

Mark Leuchtenberger
    
    Director
    
    April 11, 2007/s/ ROBERT J. PEREZ

Robert J. Perez
    
    Director
    
    April 11, 2007/s/ GREGORY D. PHELPS

Gregory D. Phelps
    
    Director
    
    April 11, 2007/s/ IAN F. SMITH

Ian F. Smith, CPA, ACA
    
    Director
    
    April 11, 2007




---



##### Table of Contents



EXHIBIT INDEX
 ExhibitNumber
    
    Description32
    
    Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, U.S.
Code)
June 27, 2013

Substance Details Report

Page 1 of 4

Classifications

Molecular Weight

Chemical Substance

Coconut oil

Chemical Abstracts Index Name

8001-31-8

Unspecified

Extractives and their physically modified derivatives. It consists primarily of the glycerides of the fatty acids capric, 

lauric, myristic, oleic and palmitic. (Cocos nucifera).

 

Former CAS Numbers

84961-48-8

8038-08-2

8038-07-1

890903-75-0

 Structure

There is no structure Information for this substance.

 Associated Identifiers

EPA Registry Name

EPA Registry Name List

Substance Status

Systematic Name List

Systematic Name

Substance Type

 Core Metadata 

Internal Tracking Number

Comment/Description

Definition

CAS Number

Molecular Formula

156901

Approved

TSN Number

EPA Identification Number

Kingdom

ICTVDB

Preferred Acronym
June 27, 2013

Substance Details Report

Page 2 of 4

 Synonym Notation T

Statutes/Regulations

2012 CDR Partial Exempt

FIFRA-Inerts

TSCA Inv

Coconut oil

Coconut oil

Coconut oil

Valid

Valid

Valid

03/22/2012

Statutes/Regulations Synonym Synonym Quality Effective Date End Date

EPA Applications/Systems

CAMEO

CAMEO

ECOTOX

ERNS

ERNS

ERNS

ERNS

ERNS

ERNS

HPVC List

HPVIS

OPPIN

TSCA Inv Syns

TSCA Inv Syns

TSCA Inv Syns

TSCATS

TSCATS

eIUR

Oils, edible: coconut

Copra

Coconut oil

Coconut butter

Copra oil

Oils, edible, coconut

Coconut oil, fatty acid

Oil, edible, coconut, fatty acid methyl ester

Coconut oil

Coconut oil

Coconut oil

Coconut oil

Coconut acidulated soapstock

Acidulated coconut soapstock

Coconut extract

Oil, coconut

Coconut oil

Coconut oil

Valid

Valid

Valid

Valid

Valid

Valid

Valid

Valid

Valid

Valid

Valid

Valid

Valid

Valid

Valid

Valid

Valid

Valid

EPA Application/System Synonym Synonym Quality Effective Date End Date

Other Sources

Below are the EPA applications/systems, statues/regulations, or other sources that track or regulate this substance. This table shows how each list refers to the substance. 
June 27, 2013

Substance Details Report

Page 3 of 4

CA Index

CUS02

CUS86

CUS90

CUS94

CUS98

HSDB

Coconut oil

Coconut oil

Coconut oil

Coconut oil

Coconut oil

Coconut oil

Coconut oil

Valid

Valid

Valid

Valid

Valid

Valid

Valid

Other Sources Synonym Synonym Quality Effective Date End Date

Ad Hoc List

There are no Synonyms of this type.

EPA Synonyms

There are no Synonyms of this type.
June 27, 2013

Substance Details Report

Page 4 of 4

 Related References

http://yosemite.epa.gov/oppts/epatscat8.nsf/ReportSearch?OpenAgent&CASNumber=8001-31-8
<PAGE>   1


                                                                     EXHIBIT 11

                         MOBILE GAS SERVICE CORPORATION
                       COMPUTATION OF EARNINGS PER SHARE
                     (in thousands, except per share data)




<TABLE>
<CAPTION>
                                              THREE MONTHS       SIX MONTHS     TWELVE MONTHS
                                             ENDED MARCH 31,   ENDED MARCH 31,  ENDED MARCH 31,
                                             1997      1996     1997    1996     1997     1996
                                             ----      ----     ----    ----     ----     ----
PRIMARY EARNINGS PER SHARE, AS SHOWN ON
     CONSOLIDATED STATEMENTS OF INCOME

<S>                                         <C>      <C>       <C>      <C>     <C>      <C>
Earnings applicable to common stock         $4,861   $5,315    6,900    7,119   $8,412   $7,615

Average common shares outstanding            3,228    3,215    3,227    3,214    3,223    3,212

Incremental shares resulting from assumed
     exercise of stock options                  26        7       21        5       16        2

Average common shares, as adjusted           3,254    3,222    3,248    3,219    3,239    3,214

Primary earnings per share (1)              $ 1.49   $ 1.65   $ 2.12   $ 2.21   $ 2.60   $ 2.37


FULLY DILUTED EARNINGS PER SHARE

Earnings applicable to common stock         $4,861   $5,314    6,900    7,119   $8,412   $7,614

Average common shares outstanding            3,228    3,215    3,227    3,214    3,223    3,212

Incremental shares resulting from assumed
     exercise of stock options                  26        9       27        9       25        4

Average common shares, as adjusted           3,254    3,224    3,254    3,223    3,248    3,216

Fully diluted earnings per share (2)        $ 1.49   $ 1.65   $ 2.12   $ 2.21   $ 2.59   $ 2.37

</TABLE>


(1)  Pursuant to footnote 2 to paragraph 14 of APB Opinion No. 15, the Company
     is not required to include common stock equivalents resulting from stock
     options when the effect is less 3%.  The Company has chosen to reflect the
     effect of such options within the computation of its earnings per share.

(2)  This calculation is submitted in accordance with Regulation S-K Item 601 
     (b)(11) although not required to be shown in the Consolidated Statements
     of Income pursuant to footnote 2 to paragraph 14 of APB Opinion No. 15
     because it results in dilution of  less than 3%.



                                      13
<PAGE>

                                                                    Exhibit 99.1


                            [OraPharma Letterhead]

March 21, 2002

Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549

Ladies and Gentlemen:

In connection with the filing of our Annual Report on Form 10-K for the fiscal
year ending December 31, 2001, which report will include audited financial
statements with an accountant's report issued by Arthur Andersen LLP
("Andersen"), we hereby inform you that Andersen has represented to us in
writing that Andersen's audit was subject to Andersen's quality control system
for the U.S. accounting and auditing practice to provide reasonable assurance
that the engagement was conducted in compliance with professional standards,
that there was appropriate continuity of Arthur Andersen personnel working on
the audit, and that there was availability of Andersen's national office for
consultation.

Sincerely,

OraPharma, Inc.

/s/ James A. Ratigan
----------------------------------------------
James A. Ratigan
Vice President and Chief Financial Officer
<TABLE> <S> <C>


<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND THE CONDENSED BALANCE SHEETS AND
IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                            <C> 
<PERIOD-TYPE>                  6-MOS
<FISCAL-YEAR-END>                           DEC-31-1998
<PERIOD-START>                              JAN-01-1998
<PERIOD-END>                                JUN-30-1998
<CASH>                                        1,754,224
<SECURITIES>                                  4,676,536
<RECEIVABLES>                                 2,067,342
<ALLOWANCES>                                    168,000
<INVENTORY>                                   1,953,873
<CURRENT-ASSETS>                             10,863,294
<PP&E>                                        3,012,840
<DEPRECIATION>                                1,862,064
<TOTAL-ASSETS>                               17,287,208
<CURRENT-LIABILITIES>                         1,897,674
<BONDS>                                               0
<PREFERRED-MANDATORY>                                 0
<PREFERRED>                                           0
<COMMON>                                        645,406
<OTHER-SE>                                   14,742,128
<TOTAL-LIABILITY-AND-EQUITY>                 17,287,208
<SALES>                                       7,343,208
<TOTAL-REVENUES>                              7,343,208
<CGS>                                         2,605,191
<TOTAL-COSTS>                                 2,605,191
<OTHER-EXPENSES>                              3,379,844
<LOSS-PROVISION>                                      0
<INTEREST-EXPENSE>                                    0
<INCOME-PRETAX>                               1,358,173
<INCOME-TAX>                                    461,800
<INCOME-CONTINUING>                             896,373
<DISCONTINUED>                                        0
<EXTRAORDINARY>                                       0
<CHANGES>                                             0
<NET-INCOME>                                    896,373
<EPS-PRIMARY>                                      0.14
<EPS-DILUTED>                                      0.14
        


</TABLE>
# DLA awards 7 contracts to small businesses at Industry Collider Day

/ Published Sept. 28, 2021
FORT BELVOIR, Va., 
Seven small businesses were awarded contracts for innovative solutions to warfighter and national security challenges through the Defense Logistics Agency’s 2021 Small Business Innovation Research Program during Industry Collider Day Sept. 8.

The awards are the result of four solicitations DLA issued before the event for research and development proposals involving several technology domains. The solicitations included detailed problem statements and challenges and drew 67 applications. 

“It’s a pleasure to join you today, especially as we get a chance to celebrate a number of truly outstanding small businesses whose work demonstrates how DLA is expanding our partnerships to transform and modernize the work we do in support of our warfighters,” DLA Acquisition Deputy Director Roxanne Banks said.

The first contract category was created to design unique identifier tag technology for tracking and tracing modular unmanned underwater vehicle systems and subsystems throughout production. Two winners were awarded contracts: Triton Systems, Inc., from Massachusetts, and Hawaii-based HNu Photonics.

In the second category, businesses were asked to consider the development of thermoplastic forming of metal components for military applications in aeronautical and space platforms. Connecticut’s Supercool Metals was awarded the Phase I contract, and the resulting technology will undergo testing.

Two award winners were selected in the rare earth metals production category, where the objective is to develop, demonstrate and stand up a rare earth metal production process in the U.S. Rare earth metals are essential to a wide range of civilian and military technologies including aircraft. Ohio’s Terves, LLC, and Massachusetts’ HELA Novel Metals, LLC, were both awarded Phase I contracts. 

The final category aims to develop, demonstrate, and stand up a rare earth separation and refining process in the U.S. Rare earth elements critical to military aircraft and weapons systems include pure metals, metal alloys and coatings. The two winners were Tusaar Inc. from Colorado and Anactisis, LLC, from Pennsylvania.  

DLA Vice Director Brad Bunn congratulated selectees. 

“You now join DLA’s long history of partnerships with small businesses. Your work will help transform and modernize our support of the warfighter,” he said. 

DLA’s Small Business Innovation Program includes three separate research and development competitive award programs, with most of the funding coming from the Office of the Secretary of Defense. The competitive opportunities include the Small Business Administration’s Small Business Innovation Research and Small Business Technology Transfer Programs, and the Undersecretary of Defense for Research and Engineering’s Rapid Innovation Fund.
#### Arlington v. Miller’s Trucking

DA 16-0719

05/02/17

2017 MT 102N

Affirmed

Dist. 3 (Granite)
# Video: DLA leadership team wishes employees a joyous holiday

/ Published Dec. 15, 2021
FORT BELVOIR, Va., 
Appreciating employees’ accomplishments is easier than ever this holiday season, Defense Logistics Agency Director Navy Vice Adm. Michelle Skubic says in a new video also starring Army Command Sgt. Maj. Tomeka O’Neal, DLA’s senior enlisted leader. 

Skubic recounts 2021 achievements such as lifesaving support to natural disasters around the world and the delivery of nearly a million doses of the COVID-19 vaccine to military treatment facilities around the globe. 

“Through all the stresses and the challenges of the pandemic, you have remained focused and never missed a beat,” she says. “I am amazed at how much we – as a team – accomplish every day.”

O’Neal shares holiday safety tips and encourages employees to check in on family members and teammates during what can be a stressful time of year. 

“I’d also encourage you to take some well-deserved time off to recharge and enjoy your family and friends,” Skubic added. “We need you back in the new year rested, energized and mission-ready.” 

The video and other DLA news and feature stories are also available at the agency’s Facebook page.
CONSENT OF INDEPENDENT CERTIFIED
                               PUBLIC ACCOUNTANTS



We  hereby  consent  to the  incorporation  by  reference,  in the  Registration
Statement  #333-18667  on  Amendment  No.  1 to  Form  SB-2  on  Form  S-3,  the
Registration  Statement  #333-39327  on Form  S-8,  the  Registration  Statement
#333-65303 on Form S-3, and the Registration  Statement  #333-82137 on Form S-8,
of our report dated February 25, 1999 (except as to Note 12 which is dated March
4, 1999 and Note 13 which is dated  July 2, 1999)  which  appears on page F-2 of
the annual report on Form 10-KSB of MyTurn.com,  Inc. (f/k/a  Compu-DAWN,  Inc.)
for the year ended  December  31, 1998 and on page F-2 of the  amendment  to the
Annual  Report on Form 10- KSB/A,  Amendment No. 1 of  MyTurn.com,  Inc. for the
year ended December 31, 1998.


                                                 /s/ Lazar Levine & Felix LLP
                                                 LAZAR LEVINE & FELIX LLP


New York, New York
February 11, 2000
[Federal Register Volume 63, Number 107 (Thursday, June 4, 1998)]
[Notices]
[Page 30482]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-14793]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Navy


Notice of Availability of Inventions for Licensing; Government-
Owned Inventions

AGENCY: Department of the Navy, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are assigned to the United States 
Government as represented by the Secretary of the Navy and are 
available for licensing by the Department of the Navy.
    Patent Application entitled ``Method for Fabricating an 
Electrically Addressable Silicon-on-Sapphire Light Valve,'' filed March 
25, 1998, Navy Case No. 79029.

ADDRESSES: Requests for copies of the patent applications cited should 
be directed to the Office of Naval Research, ONR OOCC, Ballston Tower 
One, 800 North Quincy Street, Arlington, Virginia 22217-5660 and must 
include the Navy Case numbers.

FOR FURTHER INFORMATION CONTACT: Mr. R.J. Erickson, Staff Patent 
Attorney, Office of Naval Research, ONR OOCC, Ballston Tower One, 800 
North Quincy Street, Arlington, Virginia 22217-5660, telephone (703) 
696-4001.

    (Authority: 35 U.S.C. 207, 37 CFR part 404)

    Dated: May 22, 1998.
Lou Rae Langevin,
Lt, JAGC, USN, Alternate Federal Register Liaison Officer.
[FR Doc. 98-14793 Filed 6-3-98; 8:45 am]
BILLING CODE 3810-FF-P
160 A.3d 1277

#### IN THE MATTER OF JACQUELINE ROCHELLE HARRIS, AN ATTORNEY AT LAW

May 31, 2017

ORDER

The Office of Attorney Ethics having filed with the Court a petition pursuant to *Rule*1:20—3(g) (4) and *Rule*1:20-11, seeking the immediate temporary suspension from practice of JACQUE*220LINE ROCHELLE HARRIS, formerly of ORANGE, who was admitted to the bar of this State in 1990, and who has been temporarily suspended from the practice of law since May 3, 2013, by Order of the Court filed pursuant to *Rule*1:20—17(e)(i) on April 3, 2013, and good cause appearing;

It is ORDERED that JACQUELINE ROCHELLE HARRIS is temporarily suspended from the practice of law, effective immediately, and pending her compliance with the Order filed April 3, 2013, and until the further Order of this Court; and it is further

ORDERED that JACQUELINE ROCHELLE HARRIS be restrained and enjoined from practicing law during the period of his suspension; and it is further

ORDERED that all funds, if any, currently existing or hereinafter deposited in any New Jersey financial institution maintained by JACQUELINE ROCHELLE HARRIS pursuant to *Rule*1:21-6 shall be restrained from disbursement expect on application to this Court for good cause shown, pending the further Order of this Court; and it is further

ORDERED that JACQUELINE ROCHELLE HARRIS continue to comply with *Rule*1:20-20 dealing with suspended attorneys; and it is further

ORDERED that the entire record of this matter be made a permanent part of the respondent’s file as an attorney at law of this State.
#### Lohan v Take-Two Interactive Software, Inc.

1st Dept: 142 AD3d 776

granted
#### Stanton v Oceanside Union Free Sch. Dist.

2d Dept: 140 AD3d 731 (Action No. 1)

denied